For research use only. Not for therapeutic Use.
PROTAC BCR-ABL Degrader-1(CAT: I040999) is a novel PROTAC (Proteolysis Targeting Chimera) designed to selectively degrade BCR-ABL fusion protein, a key oncogenic driver in chronic myeloid leukemia (CML) and other hematological malignancies. By leveraging the ubiquitin-proteasome system (UPS), this degrader promotes targeted BCR-ABL proteolysis, overcoming resistance mechanisms associated with traditional kinase inhibitors. It serves as a powerful tool for cancer research, particularly in studying protein degradation-based therapies and drug-resistant leukemia models. Optimized for in vitro and in vivo studies, this compound is for research use only; not for human or clinical applications.
| Catalog Number | I040999 |
| Synonyms | 4-[[4-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]-2-oxoethyl]piperazin-1-yl]methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide |
| Molecular Formula | C43H40N10O6 |
| Purity | ≥95% |
| IUPAC Name | 4-[[4-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]-2-oxoethyl]piperazin-1-yl]methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide |
| InChI | InChI=1S/C43H40N10O6/c1-26-7-12-30(22-34(26)49-43-45-17-15-32(48-43)29-4-3-16-44-23-29)46-39(56)28-10-8-27(9-11-28)24-51-18-20-52(21-19-51)25-37(55)47-33-6-2-5-31-38(33)42(59)53(41(31)58)35-13-14-36(54)50-40(35)57/h2-12,15-17,22-23,35H,13-14,18-21,24-25H2,1H3,(H,46,56)(H,47,55)(H,45,48,49)(H,50,54,57) |
| InChIKey | SEZITPLNZMSYNY-UHFFFAOYSA-N |
| SMILES | CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)CC(=O)NC4=CC=CC5=C4C(=O)N(C5=O)C6CCC(=O)NC6=O)NC7=NC=CC(=N7)C8=CN=CC=C8 |
